Wockhardt recalls over 109,000 bottles of hypertension drug in US

Tags: Wockhardt
Drugmaker Wockhardt Ltd is recalling 109,744 bottles of a high blood pressure drug in the United States after it failed a dissolution test, the US Food and Drug Administration said.

The recall of metoprolol succinate began in April and was posted on the FDA website late Wednesday. Metoprolol succinate extended release is a cheaper generic form of AstraZeneca Plc's branded drug Toprol.

A Wockhardt spokesman did not immediately respond to a request for comment on Thursday.

Dissolution tests are commonly conducted to check the time taken for the active ingredient in a drug to release into the body, and help predict how the drug performs inside the body.

Recalls of medicines by drugmakers are not uncommon, but Wockhardt is already embroiled in regulatory troubles.

Two of its manufacturing plants were banned last year from exporting to the United States after the FDA found violations of manufacturing standards that the agency believed could compromise the quality of drugs. One of those plants was making metoprolol succinate for the United States.

The FDA website said the recalled lots were manufactured at a Wockhardt plant in Mumbai.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • The world is moving away from fast food like never before

    Despite spending $1.8 billion every year on worldwide advertising and promotion, McDonald’s sales are plummeting.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schoettli

It’s time for Japan to step out of its shell

The execution of a Japanese hostage by ISIS has sho­cked ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Bubbles Sabharwal

Truth about truth

The question to ponder is, “is it the truth because ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture